secwatch.observer — SEC 8-K summary
======================================

Issuer:     Larimar Therapeutics, Inc. (LRMR)
CIK:        0001374690
Form:       8-K
Filed at:   2026-09-29T20:06:32+00:00
Accession:  0001193125-26-407331
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02
LLM model:  deepseek-v4.1-flash:cloud@v2

Larimar Therapeutics names John B. Harlow Jr. President and COO; $560K salary, 850K-share equity grant
--------------------------------------------------------------------------------

- Harlow, 51, was most recently Chief Commercial Officer at Esperion Therapeutics (Nov 2025-Sep 2026); earlier CCO roles at Melinta Therapeutics, Baudax Bio and Recro Pharma.
- Employment effective September 29, 2026: base salary $560,000 per year, $35,000 cash signing bonus, target annual bonus of 40% of salary (2026 prorated).
- Inducement awards under Nasdaq Rule 5635(c)(4): 800,000 stock options struck at the Sept 29, 2026 closing price and 50,000 restricted stock units.
- Options vest 25% on the first anniversary and the remaining 75% in 36 monthly installments; RSUs vest in four equal annual installments beginning on the first anniversary.
- Severance if terminated without cause: 9 months of salary plus 9 months COBRA; 12 months of salary plus target bonus and COBRA if terminated within one year after a change in control.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1374690/000119312526407331/0001193125-26-407331-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1374690/000119312526407331/lrmr-20260929.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-407331

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer